CN100335055C - 一种新型匹伐他汀钙可溶片组合物及其制备方法 - Google Patents
一种新型匹伐他汀钙可溶片组合物及其制备方法 Download PDFInfo
- Publication number
- CN100335055C CN100335055C CNB2005100391576A CN200510039157A CN100335055C CN 100335055 C CN100335055 C CN 100335055C CN B2005100391576 A CNB2005100391576 A CN B2005100391576A CN 200510039157 A CN200510039157 A CN 200510039157A CN 100335055 C CN100335055 C CN 100335055C
- Authority
- CN
- China
- Prior art keywords
- pitavastatin
- preparation
- soluble tablet
- pitavastatin calcium
- tablet composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960002797 pitavastatin Drugs 0.000 title abstract description 15
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 title abstract description 15
- 239000000203 mixture Substances 0.000 title abstract description 14
- 239000007944 soluble tablet Substances 0.000 title abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 3
- 229960003296 pitavastatin calcium Drugs 0.000 claims description 26
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 claims description 26
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 8
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000001361 adipic acid Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 235000011037 adipic acid Nutrition 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 5
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 12
- 210000000214 mouth Anatomy 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 238000004090 dissolution Methods 0.000 abstract description 3
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 2
- 206010056474 Erythrosis Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- -1 sodium alkoxide Chemical class 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000000770 erythrosyl group Chemical group C1([C@H](O)[C@H](O)CO1)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
试验项目 | 溶解时限 | 溶出度 | 加速试验的稳定性 |
可溶片 | <1min全溶 | 15min,80% | 未见有关物质明显增加 |
普通片/胶囊 | ≥10min崩解 | 30min,75% | 未见有关物质明显增加 |
原辅料名称 | 投料量(g) | 重量比 |
匹伐他汀钙赤藓糖醇乳糖交联羧甲基纤维素钠聚乙烯吡咯烷酮K30己二酸 | 1.0g32.0g15.0g6.0g0.5g1.0g | 1.80%57.66%27.03%11.06%0.9%1.80% |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100391576A CN100335055C (zh) | 2005-04-29 | 2005-04-29 | 一种新型匹伐他汀钙可溶片组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100391576A CN100335055C (zh) | 2005-04-29 | 2005-04-29 | 一种新型匹伐他汀钙可溶片组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1698609A CN1698609A (zh) | 2005-11-23 |
CN100335055C true CN100335055C (zh) | 2007-09-05 |
Family
ID=35474960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100391576A Expired - Fee Related CN100335055C (zh) | 2005-04-29 | 2005-04-29 | 一种新型匹伐他汀钙可溶片组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100335055C (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102861018A (zh) * | 2011-07-05 | 2013-01-09 | 南京长澳医药科技有限公司 | 一种匹伐他汀钙制剂及其制备工艺 |
CN102302452B (zh) * | 2011-09-14 | 2012-11-21 | 海南美大制药有限公司 | 匹伐他汀钙脂质体固体制剂 |
JP5190159B1 (ja) * | 2012-08-08 | 2013-04-24 | 興和株式会社 | 医薬 |
CN104367560A (zh) * | 2014-10-23 | 2015-02-25 | 万全万特制药江苏有限公司 | 一种新型匹伐他汀钙口腔崩解片组合物及其制备方法 |
CN104644587A (zh) * | 2015-03-20 | 2015-05-27 | 王雪雁 | 一种治疗心血管疾病的药物组合物的制备方法 |
CN105213339A (zh) * | 2015-10-19 | 2016-01-06 | 迪沙药业集团有限公司 | 一种匹伐他汀钙组合物 |
CN105982874A (zh) * | 2015-10-19 | 2016-10-05 | 迪沙药业集团有限公司 | 匹伐他汀钙组合物 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1430953A (zh) * | 2003-02-12 | 2003-07-23 | 刘智 | 一种防治放疗、化疗呕吐的口腔快速崩解片剂及制备方法 |
CN1473560A (zh) * | 2003-06-27 | 2004-02-11 | 辉 刘 | 中药或天然来源药用物质口腔速崩片及其制备方法 |
CN1559388A (zh) * | 2004-02-27 | 2005-01-05 | 中奇制药技术(石家庄)有限公司 | 盐酸曲马多口腔崩解片及制备方法 |
CN1562012A (zh) * | 2004-03-30 | 2005-01-12 | 刘智 | 治疗高血压、心绞痛的左氨氯地平口腔崩解片及制备方法 |
CN1562013A (zh) * | 2004-03-31 | 2005-01-12 | 江西天施康中药股份有限公司 | 用于治疗高血压病的尼索地平口腔崩解片及制备方法 |
CN1565434A (zh) * | 2003-07-03 | 2005-01-19 | 中国人民解放军军事医学科学院放射医学研究所 | 口腔内使用的莫达芬尼药物组合物 |
CN1568992A (zh) * | 2004-04-24 | 2005-01-26 | 深圳海王药业有限公司 | 氯雷他定口腔崩解片及其制备方法 |
CN1589797A (zh) * | 2004-06-10 | 2005-03-09 | 范敏华 | 盐酸洛美利嗪口腔崩解片及其制备方法 |
-
2005
- 2005-04-29 CN CNB2005100391576A patent/CN100335055C/zh not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1430953A (zh) * | 2003-02-12 | 2003-07-23 | 刘智 | 一种防治放疗、化疗呕吐的口腔快速崩解片剂及制备方法 |
CN1473560A (zh) * | 2003-06-27 | 2004-02-11 | 辉 刘 | 中药或天然来源药用物质口腔速崩片及其制备方法 |
CN1565434A (zh) * | 2003-07-03 | 2005-01-19 | 中国人民解放军军事医学科学院放射医学研究所 | 口腔内使用的莫达芬尼药物组合物 |
CN1559388A (zh) * | 2004-02-27 | 2005-01-05 | 中奇制药技术(石家庄)有限公司 | 盐酸曲马多口腔崩解片及制备方法 |
CN1562012A (zh) * | 2004-03-30 | 2005-01-12 | 刘智 | 治疗高血压、心绞痛的左氨氯地平口腔崩解片及制备方法 |
CN1562013A (zh) * | 2004-03-31 | 2005-01-12 | 江西天施康中药股份有限公司 | 用于治疗高血压病的尼索地平口腔崩解片及制备方法 |
CN1568992A (zh) * | 2004-04-24 | 2005-01-26 | 深圳海王药业有限公司 | 氯雷他定口腔崩解片及其制备方法 |
CN1589797A (zh) * | 2004-06-10 | 2005-03-09 | 范敏华 | 盐酸洛美利嗪口腔崩解片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
2003年日本上市的新药(第III部分)心血管系统用药 孙桂芬,国大亮,杜丽君,齐鲁药事,第23卷第6期 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1698609A (zh) | 2005-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100335055C (zh) | 一种新型匹伐他汀钙可溶片组合物及其制备方法 | |
CN1248690C (zh) | 一种治疗心血管疾病含盐酸雷诺嗪的口服制剂 | |
CA2751313C (en) | Process for the preparation of a pharmaceutical composition comprising ezetimibe | |
CN105658207A (zh) | 用于以低的日剂量施用的含富马酸二甲酯的药物组合物 | |
CN102657629A (zh) | 替卡格雷缓释片系统及其制备方法 | |
JPH10182436A (ja) | 固形医薬製剤 | |
CN1911211A (zh) | 雷沙吉兰口服固体制剂 | |
CN104906085A (zh) | 含有2-氧代-1-吡咯烷衍生物的药物组合物 | |
CN1538837A (zh) | 含有对乙酰氨基酚的吞咽片 | |
CN103120652B (zh) | 间苯三酚口腔崩解片及其制备方法 | |
CN101732312A (zh) | 一种石杉碱甲口服制剂及其制备方法 | |
CN1989960A (zh) | 穿心莲内酯分散片 | |
CN102727456B (zh) | 药物口腔崩解片及其制备方法 | |
CN104367560A (zh) | 一种新型匹伐他汀钙口腔崩解片组合物及其制备方法 | |
CN1297304C (zh) | 陈香露白露干混悬剂及其制备方法 | |
CN102309462A (zh) | 一种阿托伐他汀钙片剂 | |
CN101094667A (zh) | 包含他汀类药物和抗气胀剂的降胆固醇组合物 | |
CN1247195C (zh) | 水飞蓟宾口腔崩解片及其制备工艺 | |
CN1771915A (zh) | 一种用于治疗儿童感冒的氨酚麻美口腔崩解片及制备方法 | |
CN1762379A (zh) | 复方硫酸氨基葡萄糖分散片制剂及其制备方法 | |
CN101537002B (zh) | 具有优良溶出性能的双醋瑞因组合物及其制备和用途 | |
CN1254240C (zh) | 水飞蓟宾葡甲胺盐口腔崩解片及其制备工艺 | |
CN101152187A (zh) | 依普利酮药物组合物 | |
CN1247203C (zh) | 豆腐果苷口腔崩解片及其制备方法 | |
CN100486566C (zh) | 苏冰口腔速崩片及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Jiangsu Yang Yang Pharmaceutical Co.,Ltd. Assignor: Xing Weifan Contract record no.: 2011320000369 Denomination of invention: Pitavastatin soluble tablet composition and preparation method thereof Granted publication date: 20070905 License type: Exclusive License Open date: 20051123 Record date: 20110323 |
|
ASS | Succession or assignment of patent right |
Owner name: NANJING QUAKE BIOPHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XING WEIFAN Effective date: 20110607 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 EAST UNIT, BUILDING 12, NO. 2, QIJIA BRIDGE, NANJING CITY, JIANGSU PROVINCE TO: 211100 NO. 118, TIANYUAN EAST ROAD, SCIENCE PARK, JIANGNING DISTRICT, NANJING CITY, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110607 Address after: 211100, No. 118 East Tianyuan Road, Jiangning District, Jiangsu, Nanjing Patentee after: Nanjing Quirke Biological Medicine Co.,Ltd. Address before: 210009 Jiangsu Province, Nanjing City Bridge No. 2 building 12 East Patentee before: Xing Weifan |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Jiangsu Yang Yang Pharmaceutical Co.,Ltd. Assignor: Xing Weifan Contract record no.: 2011320000369 Date of cancellation: 20110610 |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070905 |
|
CF01 | Termination of patent right due to non-payment of annual fee |